The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'

Julian Lindsay, Michael Joseph Dooley, Jennifer H Martin, Michael Fay, Alison Kearney, Mohsina Khatun, Michael A Barras

Research output: Contribution to journalArticleResearchpeer-review

46 Citations (Scopus)


Results: A total of 61 patients were recruited. The OncPal Deprescribing Guideline matched 94 of 617 medicines to the expert panel with a Kappa value of 0.83 [95 CI (0.76, 0.89)] demonstrating an `outstanding? concordance. Forty-three (70 ) patients were taking at least one PIM, with 21.4 of the total medicines assessed identified as PIMs. The medication-associated cost per patient/month was AUD 26.71. Purpose: Current data suggests that potentially inappropriate medicines (PIMs) are common in palliative cancer patients; however, there is a lack of criteria to assist clinicians in identifying PIMs in these patients. The aims of this study were to design and validate a deprescribing guideline for palliative cancer patients and to undertake a descriptive analysis of the identified PIMs. Methods: This prospective, non-interventional cohort study consisted of four major stages: developing an `OncPal Deprescribing Guideline? from current evidence, the prospective recruitment of consecutive palliative cancer inpatients with an estimated
Original languageEnglish
Pages (from-to)71 - 78
Number of pages8
JournalSupportive Care in Cancer
Issue number1
Publication statusPublished - 2015

Cite this